INTENSE PULSED LIGHT (IPL) TREATMENT FOR DUPILUMAB INDUCED OCULAR SURFACE DISEASE (DIOSD) A NOVEL CASE REPORT

Article Sidebar

PDF
Published: Jan 3, 2022
DOI: https://doi.org/10.22374/jded.v5i1.40
Keywords:
Dupilumab Induced Ocular Surface Disease, Atopic Dermatitis, Intense Pulsed Light

Main Article Content

Sathi Maiti
Periman Eye Institute, Seattle, WA, USA
Laura M Periman
Periman Eye Institute, Seattle, WA, USA
Natasha Balani
Periman Eye Institute, Seattle, WA, USA

Abstract

Purpose
To report a case of dupilumab induced ocular surface disease (DIOSD) managed with intense pulsed light (IPL) as an effective adjunct therapy to topical steroids and topical immunomodulator lifitegrast.
Methods
Discussion of a patient’s case with accompanying anterior segment and meibography photos with diagnosed DIOSD for which adjunct therapy with IPL was an effective treatment after limited relief from and difficulty with adherence to traditional treatment with topical steroids and lifitegrast ophthalmic solutions. Conclusion
This case demonstrates the complexity of management required to treat patients with DIOSD and its chronic nature. IPL as a nonpharmaceutical adjunct therapy to topical steroids and immunomodulators in the treatment of DIOSD showed improved signs and symptoms of DIOSD.

Downloads

Download data is not yet available.

Article Details

Issue
Vol. 5 No. 1 (2022): JDED
Section
Articles

Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.

Author Biographies

Sathi Maiti, Periman Eye Institute, Seattle, WA, USA

Department of Ocular Surface Disease and Clinical Research, Periman Eye Institute, Seattle, WA, USA

Laura M Periman, Periman Eye Institute, Seattle, WA, USA

Department of Dry Eye Services and Clinical Research, Periman Eye Institute, Seattle, WA, USA

Natasha Balani, Periman Eye Institute, Seattle, WA, USA

Periman Eye Institute, Seattle, WA, USA

References

1. Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, Zhang D, Fan C, Holtappels G, Hamilton JD, Grabher A, Graham NMH, Pirozzi G, Bachert C. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019 Apr;74(4):743-752. doi: 10.1111/all.13685. Epub 2019 Jan 21. PMID: 30488542; PMCID: PMC6590149. http://https://pubmed.ncbi.nlm.nih.gov/30488542/
2. Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: Basic aspects and applications to allergic diseases. Allergol Int. 2020 Apr;69(2):187-196. doi: 10.1016/j.alit.2020.01.002. Epub 2020 Jan 30. PMID: 32007360. http://https://pubmed.ncbi.nlm.nih.gov/32007360/
3. Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegräber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6:1778–80. http://https://pubmed.ncbi.nlm.nih.gov/29432961/
4. Popiela, M.Z., Barbara, R., Turnbull, A.M.J. et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (2021). https://doi.org/10.1038/s41433-020-01379-9
5. Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2020 Jun;104(6):776-779. doi: 10.1136/bjophthalmol-2019-315010. Epub 2019 Sep 25. PMID: 31554632. http://https://pubmed.ncbi.nlm.nih.gov/31554632/
6. Zirwas MJ, Wulff K, Beckman K. Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report. JAAD Case Rep. 2018;5(1):34-36. Published 2018 Dec 4. doi:10.1016/j.jdcr.2018.10.016. http://https://pubmed.ncbi.nlm.nih.gov/30555883/
7. Johanna Tukler Henriksson, Terry G. Coursey, David B. Corry, Cintia S. De Paiva, Stephen C. Pflugfelder; IL-13 Stimulates Proliferation and Expression of Mucin and Immunomodulatory Genes in Cultured Conjunctival Goblet Cells. Invest. Ophthalmol. Vis. Sci. 2015;56(8):4186-4197. doi: https://doi.org/10.1167/iovs.14-15496.
8. Agnihotri G, Shi K, Lio PA. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis. Drugs R D. 2019;19(4):311-318. doi:10.1007/s40268-019-00288-x. http:// https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890653/
9. Ferreira F, Torres T. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs in Context 2020; 9: 2020-2-3. DOI: 10.7573/dic.2020-2-3. http://https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216785/
10. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3): 459–473. http://doi.org/10.1111/bjd.17869
11. Giannaccare G, Taroni L, Senni C, Scorcia V. Intense Pulsed Light Therapy In The Treatment Of Meibomian Gland Dysfunction: Current Perspectives. Clin Optom (Auckl). 2019;11:113-126. Published 2019 Oct 17. doi:10.2147/OPTO.S217639. http://https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802620/
12. Raulin C, Greve B, Grema H. IPL technology: a review. Lasers Surg Med. 2003;32:78–87. doi:10.1002/lsm.10145. http://https://pubmed.ncbi.nlm.nih.gov/12561039/
13. Toyos R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year Retrospective Study. Photomed Laser Surg. 2015;33:41–46. doi:10.1089/pho.2014.3819. htt://https://pubmed.ncbi.nlm.nih.gov/25594770/
14. Dell SJ. Intense pulsed light for evaporative dry eye disease. Clin Ophtalmol. 2017;11:1167–1173. doi:10.2147/OPTH.S139894. http://https://pubmed.ncbi.nlm.nih.gov/28790801/